Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 27, 2026EP EuropaceOpen Access

Association of diabetes mellitus status and clinical outcomes of edoxaban in patients with atrial fibrillation: a sub-analysis from the ETNA-AF Asian registry

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does diabetes mellitus status increase the risk of thromboembolic and bleeding events in patients with atrial fibrillation treated with edoxaban?

Population

3,299 patients with atrial fibrillation from South Korea, Taiwan, Thailand, and Hong Kong receiving edoxaban…

Comparison

Presence of diabetes mellitus, with all patients… vs Patients without diabetes mellitus, receiving…

Design

Cohort

Follow-up

2 years

Authors

TCT F C ChaoECE K ChoiHTH F Tse

Discussion

Loading...

Member takes

Overview

DM associated with higher major GI bleeding on edoxaban in AF; hypothesis-generating and should not yet change practice.

Key Points

  • This study aims to evaluate how diabetes mellitus status affects clinical outcomes in atrial fibrillation patients treated with edoxaban over two years.
  • Prospective, observational study involving patients with atrial fibrillation in South Korea, Taiwan, Thailand, and Hong Kong receiving edoxaban.
  • Clinical outcomes were analyzed using annualized event rates and Kaplan-Meier curves, stratified by diabetes status.
  • Cox proportional hazards regression was employed to assess differences in outcomes based on diabetes management.
  • Patients with diabetes had a higher rate of major gastrointestinal bleeding (HR 2.97, 95% CI 1.32–6.69, P=0.009) compared to those without diabetes.
  • The net clinical outcome was significantly worse for patients with diabetes (HR 1.37, 95% CI 1.01–1.87, P=0.046).
  • No significant increase in ischemic stroke risk was found in diabetic patients compared to non-diabetic patients.

Structured PICO

Does diabetes mellitus status increase the risk of thromboembolic and bleeding events in patients with atrial fibrillation treated with edoxaban?

P
Population
3,299 patients with atrial fibrillation from South Korea, Taiwan, Thailand, and Hong Kong receiving edoxaban at baseline.
I
Intervention
Presence of diabetes mellitus (stratified by insulin use: DM on insulin and DM not on insulin), with all patients receiving background edoxaban therapy.
C
Comparator
Patients without diabetes mellitus, receiving background edoxaban therapy.
O
Outcome
Clinical outcomes including ischaemic stroke (IS)/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and all-cause death (ACD) over a 2-year follow-up.hard clinical

In Asian patients with atrial fibrillation taking edoxaban, diabetes mellitus is associated with a significantly higher risk of major GI bleeding and worse net clinical outcomes, but not a significantly higher risk of stroke.

Cite This Study

Chao et al. (2026) studied this question.

synapsesocial.com/papers/6a3f97ce125782b61d8659dehttps://doi.org/10.1093/europace/euag105.339
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of renal impairment and other high bleeding risk factors on clinical outcomes among Asian patients with atrial fibrillation on edoxaban: a post hoc analysis of the ETNA-AF program2026
  2. 2Edoxaban Antithrombotic Therapy in Diabetic Patients with Atrial Fibrillation and Stable Coronary Artery Disease: The EPIC-CAD Trial2026
  3. 3Impact of Age on Bleeding, Stroke, and Mortality in Edoxaban-Treated Patients with Atrial Fibrillation: Results from the ETAF-TR Registry2026
  4. 4Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.2025
  5. 5From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe2026